The DOI matches its Crossref record; 64 of the 64 references it cites were found in a registry or an index.
Prioritization of cancer therapeutic targets using CRISPR–Cas9 screens
Open accessPublished version of a preprint
Abstract
Functional genomics approaches can overcome limitations-such as the lack of identification of robust targets and poor clinical efficacy-that hamper cancer drug development. Here we performed genome-scale CRISPR-Cas9 screens in 324 human cancer cell lines from 30 cancer types and developed a data-driven framework to prioritize candidates for cancer therapeutics. We integrated cell fitness effects with genomic biomarkers and target tractability for drug development to systematically prioritize new targets in defined tissues and genotypes. We verified one of our most promising dependencies, the Werner syndrome ATP-dependent helicase, as a synthetic lethal target in tumours from multiple cancer types with microsatellite instability. Our analysis provides a resource of cancer dependencies, generates a framework to prioritize cancer drug targets and suggests specific new targets. The principles described in this study can inform the initial stages of drug development by contributing to a new, diverse and more effective portfolio of cancer drug targets.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“the MSI that often leads to cancer simultaneously makes the inhibition of Werner syndrome ATP-dependent helicase (WRN) lethal to the tumor cells62,63”
From The origins and genetic interactions of KRAS mutations are allele- and tissue-specific (2021) · cites this paper as [62]
In the citing paper
“''Fitness Scores'' that were calculated from large-scale genome-wide CRISPR/Cas9 screens across 31 independent CRC cell lines and represent a quantitative measure of the reduction of cell viability elicited by a gene inactivation via CRISPR/Cas9 (https://score.depmap.sanger.ac.uk) (Behan et al., 2019;van der Meer et al., 2019).”
From Degradation of CCNK/CDK12 is a druggable vulnerability of colorectal cancer (2021) · cites this paper as Behan et al., 2019
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Subramanian, A., Tamayo, P., Mootha, V. K., Mukherjee, S., Ebert, B. L., Gillette, M. A., Paulovich, A., Pomeroy, S. L., Golub, T. R., Lander, E. S., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0506580102 · Cited by 53,625
limma powers differential expression analyses for RNA-sequencing and microarray studies
Ritchie, M. E., Phipson, B., Wu, D., Hu, Y., Law, C. W., Shi, W., & Smyth, G. K. (2015) · Nucleic Acids Research · doi:10.1093/nar/gkv007 · Cited by 40,458
Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012
Ferlay, J., Soerjomataram, I., Dikshit, R., Eser, S., Mathers, C., Rebelo, M., Parkin, D. M., Forman, D., & Bray, F. (2015) · International Journal of Cancer · doi:10.1002/ijc.29210 · Cited by 28,766
Differential expression analysis for sequence count data
Anders, S., & Huber, W. (2010) · Genome Biology · doi:10.1186/gb-2010-11-10-r106 · Cited by 15,581
Statistical significance for genomewide studies
Storey, J. D., & Tibshirani, R. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1530509100 · Cited by 9,692
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
Le, D. T., Uram, J. N., Wang, H., Bartlett, B. R., Kemberling, H., Eyring, A. D., Skora, A. D., Luber, B. S., Azad, N. S., Laheru, D., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1500596 · Cited by 9,377
voom: precision weights unlock linear model analysis tools for RNA-seq read counts
Law, C. W., Chen, Y., Shi, W., & Smyth, G. K. (2014) · Genome Biology · doi:10.1186/gb-2014-15-2-r29 · Cited by 6,155
Genome-scale CRISPR-Cas9 knockout screening in human cells
Shalem, O., Sanjana, N. E., Hartenian, E., Shi, X., Scott, D. A., Mikkelsen, T. S., Heckl, D., Ebert, B. L., Root, D. E., Doench, J. G., et al. (2014) · Science · doi:10.1126/science.1247005 · Cited by 5,234
Zehir, A., Benayed, R., Shah, R. H., Syed, A., Middha, S., Kim, H. R., Srinivasan, P., Gao, J., Chakravarty, D., Devlin, S. M., et al. (2017) · Nature Medicine · doi:10.1038/nm.4333 · Cited by 3,380 · cited 1×
“Most patients however do not benefit from such targeted therapies in part due to limited knowledge of candidate targets(Zehir et al. 2017).”
Defining a Cancer Dependency Map
Tsherniak, A., Vazquez, F., Montgomery, P. G., Weir, B. A., Kryukov, G., Cowley, G. S., Gill, S., Harrington, W. F., Pantel, S., Krill-Burger, J. M., et al. (2017) · Cell · doi:10.1016/j.cell.2017.06.010 · Cited by 3,276
Cited by
Sorted by citations
Items 501–600 of 999
Birkeälv, S., Harland, M., Matsuyama, L. S. A. S., Rashid, M., Mehta, I., Laye, J. P., Haase, K., Mell, T., Iyer, V., Robles‐Espinoza, C. D., et al. (2022) · The Journal of Pathology · doi:10.1002/path.6019 · Cited by 17
Usluer, S., Hallast, P., Crepaldi, L., Zhou, Y., Urgo, K., Dinçer, C., Su, J., Noell, G. G., Alasoo, K., Garwany, O. E., et al. (2023) · Stem Cell Reports · doi:10.1016/j.stemcr.2023.03.008 · Cited by 17
Kuppers, D. A., Linton, J., Ortiz‐Espinosa, S., McKenna, K. M., Rongvaux, A., & Paddison, P. J. (2023) · PLoS ONE · doi:10.1371/journal.pone.0287052 · Cited by 15
Stuart, D. D., Guzman-Perez, A., Brooijmans, N., Jackson, E. L., Kryukov, G. V., Friedman, A. A., & Hoos, A. (2023) · Cancer Discovery · doi:10.1158/2159-8290.cd-23-0280 · Cited by 19
Culliford, R., Lawrence, S. E. D., Mills, C., Tippu, Z., Chubb, D., Cornish, A. J., Browning, L., Kinnersley, B., Bentham, R. B., Sud, A., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-49692-1 · Cited by 20
Tejwani, V., Carroll, T. D., Macartney, T., Bandau, S., Alabert, C., Saredi, G., Toth, R. L., & Rouse, J. W. (2024) · Scientific Reports · doi:10.1038/s41598-024-71160-5 · Cited by 17
Emerging Gene-editing nano-therapeutics for Cancer
Nujoom, N., Koyakutty, M., Biswas, L., Rajkumar, T., & Nair, S. V. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e39323 · Cited by 16
Perron, U., Grassi, E., Chatzipli, A., Viviani, M., Karakoç, E., Trastulla, L., Brochier, L. M., Isella, C., Zanella, E. R., Klett, H., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-53163-y · Cited by 17
Self-citationNoto, A., Valenzisi, P., Feo, F. D., Fratini, F., Kulikowicz, T., Sommers, J. A., Perdichizzi, B., Semproni, M., Palermo, V., Crescenzi, M., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-55958-z · Cited by 17
Bio-primed machine learning to enhance discovery of relevant biomarkers
Henke, D., Renwick, A., Zoeller, J. R., Meena, J. K., Neill, N. J., Bowling, E. A., Meerbrey, K. L., Westbrook, T. F., & Simon, L. M. (2025) · npj Precision Oncology · doi:10.1038/s41698-025-00825-9 · Cited by 18
Jaiswal, A., Gautam, P., Pietilä, E. A., Timonen, S., Nordström, N., Akimov, Y. A., Sipari, N., Tanoli, Z., Fleischer, T., Lehti, K., et al. (2021) · Molecular Systems Biology · doi:10.15252/msb.20209526 · Cited by 15
Importance of the biomass formulation for cancer metabolic modeling and drug prediction
Garcia, M. M., Pacheco, M. P., Bintener, T., Presta, L., & Sauter, T. (2021) · iScience · doi:10.1016/j.isci.2021.103110 · Cited by 15
Evolution of precision oncology‐guided treatment paradigms
DasGupta, R., Yap, A., Yong, E. Y., & Chia, S. (2022) · WIREs Mechanisms of Disease · doi:10.1002/wsbm.1585 · Cited by 17
Chen, T., Dumas, M., Watson, R., Vincoff, S., Peng, C., Zhao, L., Hong, L., Pertsemlidis, S., Shaepers-Cheu, M., Wang, T. Z., et al. (2023) · PubMed · doi:10.48550/arxiv.2310.03842 · Cited by 24
A human metabolic map of pharmacological perturbations reveals drug modes of action
Schuhknecht, L., Ortmayr, K., Jänes, J., Bläsi, M., Panoussis, E., Bors, S., Dorčaková, T., Fuhrer, T., Beltrão, P., & Zampieri, M. (2025) · Nature Biotechnology · doi:10.1038/s41587-024-02524-5 · Cited by 16
Mutant p53 protein accumulation is selectively targetable by proximity-inducing drugs
Sadagopan, A., Carson, M., Zamurs, E. J., Garaffo, N., Chang, H.-J., Schreiber, S. L., Meyerson, M. M., & Gibson, W. J. (2025) · Nature Chemical Biology · doi:10.1038/s41589-025-02051-7 · Cited by 26
Alendar, A., Lambooij, J.-P., Bhaskaran, R., Lancini, C., Song, J., van Vugt, H., Snoek, M., & Berns, A. J. M. (2020) · PLoS ONE · doi:10.1371/journal.pone.0233394 · Cited by 16
Asakawa, A., Kawade, G., Kurata, M., Fukuda, S., Onishi, I., Kinowaki, Y., Ishibashi, S., Ikeda, M., Watabe, S., Kobayashi, M., et al. (2022) · Lung Cancer · doi:10.1016/j.lungcan.2022.01.012 · Cited by 15
A network of DZF proteins controls alternative splicing regulation and fidelity
Haque, N., Will, A., Cook, A. G., & Hogg, J. R. (2023) · Nucleic Acids Research · doi:10.1093/nar/gkad351 · Cited by 15
Ye, Q., Raese, R. A., Luo, D., Feng, J., Xin, W., Dong, C., Qian, Y. R., & Guo, N. L. (2023) · Cells · doi:10.3390/cells12141917 · Cited by 15
Lu, T., Xu, R., Wang, C., Zhou, X., Parra-Medina, R. S., Díaz‐Peña, R., Peng, B., & Zhang, L. (2023) · Journal of Thoracic Disease · doi:10.21037/jtd-23-795 · Cited by 15
Global analysis of suppressor mutations that rescue human genetic defects
Ünlü, B., Pons, C., Ho, U. L., Batté, A., Aloy, P., & van Leeuwen, J. S. (2023) · Genome Medicine · doi:10.1186/s13073-023-01232-0 · Cited by 14
The power and the promise of synthetic lethality for clinical application in cancer treatment
Liu, Q., Yang, Z., Tang, Q.-H., Wang, W.-E., Chu, D.-S., Ji, J.-F., Fan, Q.-Y., Jiang, H., Yang, Q.-X., Zhang, H., et al. (2024) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2024.116288 · Cited by 17
Li, Y., Zhu, L., Mao, J., Zheng, H., Hu, Z., Yang, S., Mao, T., Zhou, T., Cao, P., Wu, H., et al. (2024) · MedComm · doi:10.1002/mco2.483 · Cited by 15
Papakyriacou, I., Kutkaite, G., Bedós, M. R., Nagarajan, D., Alford, L. P., Menden, M. P., & Mao, Y. (2024) · Nature Communications · doi:10.1038/s41467-024-47987-x · Cited by 18
Programming tumor evolution with selection gene drives to proactively combat drug resistance
Leighow, S. M., Reynolds, J., Sokirniy, I., Yao, S., Yang, Z., Inam, H., Wodarz, D., Archetti, M., & Pritchard, J. R. (2024) · Nature Biotechnology · doi:10.1038/s41587-024-02271-7 · Cited by 15
Manen-Freixa, L., & Antolín, A. A. (2024) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2024.2376643 · Cited by 15
Hároníková, L., Zatloukalová, P., Kucerikova, M., Friedlová, N., Tylichová, Z., Kokas, F. Z., Hupp, T. R., Coates, P. J., & Vojtěšek, B. (2024) · Cellular & Molecular Biology Letters · doi:10.1186/s11658-024-00637-y · Cited by 15
Are we failing in treatment of adrenocortical carcinoma? Lights and shadows of molecular signatures
Grisanti, S., Cosentini, D., Laganà, M., Abate, A., Rossini, E., Sigala, S., & Berruti, A. (2019) · Current Opinion in Endocrine and Metabolic Research · doi:10.1016/j.coemr.2019.07.007 · Cited by 15
CancerTracer: a curated database for intrapatient tumor heterogeneity
Wang, C., Yang, J., Luo, H., Wang, K., Wang, Y., Xiao, Z. J., Tao, X., Jiang, H., & Cai, H. (2019) · Nucleic Acids Research · doi:10.1093/nar/gkz1061 · Cited by 15
Towards the routine use of in silico screenings for drug discovery using metabolic modelling
Bintener, T., Pacheco, M. P., & Sauter, T. (2020) · Biochemical Society Transactions · doi:10.1042/bst20190867 · Cited by 17
Development of targeted therapy of NRF2high esophageal squamous cell carcinoma
Paiboonrungruang, C., Simpson, E., Xiong, Z., Huang, C. D., Li, J., Li, Y., & Chen, X. L. (2021) · Cellular Signalling · doi:10.1016/j.cellsig.2021.110105 · Cited by 15
Pan-cancer analysis of non-oncogene addiction to DNA repair
Bermúdez-Guzmán, L. (2021) · Scientific Reports · doi:10.1038/s41598-021-02773-3 · Cited by 17
Use of viral motif mimicry improves the proteome-wide discovery of human linear motifs
Wadie, B., Kleshchevnikov, V., Sandaltzopoulou, E., Benz, C., & Petsalaki, E. (2022) · Cell Reports · doi:10.1016/j.celrep.2022.110764 · Cited by 15
Yang, X., Cruz, M. I., Nguyen, E. V., Huang, C., Schittenhelm, R. B., Luu, J., Cowley, K. J., Shin, S., Nguyen, L. K., Sian, T. C. C. L. K., et al. (2023) · Oncogene · doi:10.1038/s41388-023-02594-w · Cited by 15
The Mutator Phenotype: Adapting Microbial Evolution to Cancer Biology
Natali, F., & Rancati, G. I. (2019) · Frontiers in Genetics · doi:10.3389/fgene.2019.00713 · Cited by 15
VHL Synthetic Lethality Signatures Uncovered by Genotype-Specific CRISPR-Cas9 Screens
Sun, N., Petiwala, S. M., Lu, C., Hutti, J. E., Hu, M., Hu, M., Domanus, M. H., Mitra, D., Addo, S. N., Miller, C. P., et al. (2019) · The CRISPR Journal · doi:10.1089/crispr.2019.0018 · Cited by 15
Werner Syndrome Protein Expression in Breast Cancer
Savva, C., Sadiq, M. T., Sheikh, O., Karim, S., Trivedi, S., Green, A. R., Rakha, E. A., Madhusudan, S., & Arora, A. (2020) · Clinical Breast Cancer · doi:10.1016/j.clbc.2020.07.013 · Cited by 15
Kim, E., Novak, L. C., Lin, C., Colic, M., Bertolet, L. L., Gheorghe, V., Bristow, C. A., & Hart, T. (2022) · Genome biology · doi:10.1186/s13059-022-02712-z · Cited by 14
Scalable and universal prediction of cellular phenotypes enables in silico experimentsPreprint
Ji, Y., Tejada-Lapuerta, A., Schmacke, N. A., Zheng, Z., Zhang, X., Khan, S., Rothenaigner, I., Tschuck, J., Hadian, K., Hornung, V., et al. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.08.12.607533 · Cited by 18
Adnan Awad, S., Dufva, O., Klievink, J., Karjalainen, E., Ianevski, A., Pietarinen, P., Kim, D., Potdar, S., Wolf, M., Lotfi, K., et al. (2024) · Cell Reports Medicine · doi:10.1016/j.xcrm.2024.101521 · Cited by 14
“16 In addition, this functional genomics tool can be applied to decipher the potential mechanisms of resistance and sensitization to candidate targeted drugs and immunotherapies.”
High-Throughput CRISPR Screening in Hematological Neoplasms
Ancos-Pintado, R., Bragado-García, I., Morales, M. L., García-Vicente, R., Arroyo-Barea, A., Rodríguez-García, A., Martínez-López, J., Linares, M., & Hernández-Sánchez, M. (2022) · Cancers · doi:10.3390/cancers14153612 · Cited by 15
Law, P., Studd, J. B., Smith, J. S., Vijayakrishnan, J., Harris, B. T., Mandelia, M., Mills, C., Dunlop, M. G., & Houlston, R. S. (2024) · Nature Genetics · doi:10.1038/s41588-024-01900-w · Cited by 16
Natural products targeting cancer cell dependency
Shi, C., Yang, E. J., Tao, S., Ren, G., Mou, P. K., & Shim, J. S. (2021) · The Journal of Antibiotics · doi:10.1038/s41429-021-00438-x · Cited by 15
Ketola, K., Kaljunen, H., Taavitsainen, S., Kaarijärvi, R., Järvelä, E., Rodríguez–Martín, B., Haase, K., Woodcock, D. J., Tubío, J. M. C., Wedge, D. C., et al. (2021) · Cancer Research · doi:10.1158/0008-5472.can-21-0371 · Cited by 15
Zhang, Z.-Y., Ding, Y., Ezhilarasan, R., Lhakhang, T. W., Wang, Q., Yang, J., Modrek, A. S., Zhang, H., Tsirigos, A., Futreal, P. A., et al. (2022) · Cell Discovery · doi:10.1038/s41421-022-00462-7 · Cited by 18
The roles of KLHL family members in human cancers.
Ye, G., Wang, J., Yang, W., Li, J., Meng, Y., & Jin, X. (2022) · PubMed Central · Cited by 13
Cooper, S., Coelho, M. A., Strauß, M. E., Gontarczyk, A. M., Wu, Q., Garnett, M. J., Marioni, J. C., & Bassett, A. R. (2024) · Genome biology · doi:10.1186/s13059-024-03169-y · Cited by 12
Self-citationCRISPR/Cas9-Mediated Customizing Strategies for Adoptive T-Cell Therapy
Park, H., Kang, Y. K., & Shim, G. (2024) · Pharmaceutics · doi:10.3390/pharmaceutics16030346 · Cited by 16
Bulanova, D. R., Akimov, Y. A., Senkowski, W., Oikkonen, J., Gall-Mas, L., Timonen, S., Elmadani, M., Hynninen, J., Hautaniemi, S., Aittokallio, T. A., et al. (2024) · Science Advances · doi:10.1126/sciadv.adj1564 · Cited by 16
CytoCellDB: a comprehensive resource for exploring extrachromosomal DNA in cancer cell lines
Fessler, J., Ting, S., Yi, H., Haase, S., Chen, J., Gulec, S., Wang, Y., Smyers, N., Goble, K., Cannon, D., et al. (2024) · NAR Cancer · doi:10.1093/narcan/zcae035 · Cited by 14
Tsiami, F., Lago, C., Pozza, N., Piccioni, F., Zhao, X., Luelsberg, F., Root, D. E., Tiberi, L., Kool, M., Schittenhelm, J., et al. (2024) · Acta Neuropathologica Communications · doi:10.1186/s40478-024-01831-x · Cited by 15
MorPhiC Consortium: towards functional characterization of all human genes
Adli, M., Przybyla, L., Burdett, T., Burridge, P. W., Cacheiro, P., Chang, H. Y., Engreitz, J., Gilbert, L. A., Greenleaf, W. J., Hsu, L.-I., et al. (2025) · Nature · doi:10.1038/s41586-024-08243-w · Cited by 21
Fidelito, G., Todorovski, I., Cluse, L. A., Vervoort, S. J., Taylor, R. A., & Watt, M. J. (2025) · Cell Reports · doi:10.1016/j.celrep.2025.115470 · Cited by 14
Han, F., Qi, G., Li, R., Peng, J., Shi, Y., Yuan, C., Kong, B., & Ma, H. (2025) · Cell Death and Disease · doi:10.1038/s41419-025-07647-4 · Cited by 14
A next-generation dual guide CRISPR system for genetic interaction library screening
Burgold, T., Karakoç, E., Gonçalves, E., Barrio‐Hernandez, I., Dwane, L., Silva, R., Souster, E., Sharma, M., Beck, A., Koh, C. C., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-67256-9 · Cited by 13
Self-citationOyama, R., Kito, F., Takahashi, M., Hattori, E., Noguchi, R., Takai, Y., Sakumoto, M., Qiao, Z., Toki, S., Sugawara, M., et al. (2020) · Cancer Cell International · doi:10.1186/s12935-020-1128-z · Cited by 14
Epistasis and evolutionary dependencies in human cancers
Mina, M., Iyer, A., & Ciriello, G. (2022) · Current Opinion in Genetics & Development · doi:10.1016/j.gde.2022.101989 · Cited by 13
ML-DTD: Machine Learning-Based Drug Target Discovery for the Potential Treatment of COVID-19
Saha, S., Chatterjee, P., Halder, A. K., Nasipuri, M., Basu, S., & Plewczyński, D. (2022) · Vaccines · doi:10.3390/vaccines10101643 · Cited by 14
HIRA loss transforms FH -deficient cells
Valcárcel-Jiménez, L., Rogerson, C., Yong, C., Schmidt, C., Yang, M. H., Cremades-Rodelgo, M., Harle, V. J., Offord, V., Wong, K., Mora, A., et al. (2022) · Science Advances · doi:10.1126/sciadv.abq8297 · Cited by 14
RBM39 degrader invigorates innate immunity to eradicate neuroblastoma despite cancer cell plasticity
Singh, S. V., Fang, J., Jin, H., de Velde, L.-A. V., Cortes, A., Chen, J., Natarajan, S., Poon, E., Wu, Q., Morton, C. L., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-63979-x · Cited by 14
Widespread perturbation of ETS factor binding sites in cancer
Pro, S. C., Hook, H., Bray, D., Berenzy, D., Moyer, D. C., Yin, M., Labadorf, A. T., Tewhey, R., Siggers, T., & Bass, J. I. F. (2023) · Nature Communications · doi:10.1038/s41467-023-36535-8 · Cited by 14
Ohnmacht, A. J., Rajamani, A., Avar, G., Kutkaite, G., Gonçalves, E., Saur, D., & Menden, M. P. (2023) · Communications Biology · doi:10.1038/s42003-023-05198-y · Cited by 12
Self-citationA dual sgRNA library design to probe genetic modifiers using genome-wide CRISPRi screens
Guna, A., Page, K. R., Replogle, J. M., Esantsi, T. K., Wang, M. L., Weissman, J. S., & Voorhees, R. M. (2023) · BMC Genomics · doi:10.1186/s12864-023-09754-y · Cited by 14
FABP5 Inhibition against PTEN-Mutant Therapy Resistant Prostate Cancer
Swamynathan, M. M., Mathew, G., Aziz, A., Gordon, C., Hillowe, A., Wang, H., Jhaveri, A., Kendall, J., Cox, H., Giarrizzo, M., et al. (2023) · Cancers · doi:10.3390/cancers16010060 · Cited by 15
CRISPR/Cas9: an overview of recent developments and applications in cancer research
Devi, S. N., Rana, R., Malik, P., & Ganguly, N. K. (2024) · International Journal of Surgery · doi:10.1097/js9.0000000000001081 · Cited by 14
Yuan, H., Liu, R., Gao, Z.-Y., Zhong, L.-T., Zhou, Y.-C., Tan, J., Huang, Z., Li, Z., & Chen, S.-B. (2024) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2024.129711 · Cited by 13
Liu, J., Mi, L., Yang, J., Qian, H., Liu, H., Wen, W., Zhang, X., Wu, Z., & Wang, S. (2024) · Sensors and Actuators B Chemical · doi:10.1016/j.snb.2024.135708 · Cited by 13
Analyzing the functional effects of DNA variants with gene editing
Cooper, S., Obolenski, S., Waters, A. J., Bassett, A. R., & Coelho, M. A. (2024) · Cell Reports Methods · doi:10.1016/j.crmeth.2024.100776 · Cited by 14
Huang, Y.-Z., Sang, M., Xi, P.-W., Xu, R.-X., Cai, M., Wang, Z.-W., Zhao, J., Li, Y.-H., Yin, P., Ding, Q., et al. (2024) · Cancer Research · doi:10.1158/0008-5472.can-23-2738 · Cited by 13
Precision preclinical modeling to advance cancer treatment
Gutmann, D. H., Boehm, J. S., Karlsson, E. K., Padron, E., Seshadri, M., WALLIS, D. E., & Snyder, J. C. (2024) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djae249 · Cited by 14
eIF4F controls ERK MAPK signaling in melanomas with BRAF and NRAS mutations
Valčíková, B., Vadovičová, N., Smolkova, K., Zacpalova, M., Krejčı́, P., Lee, S., Rauch, J., Kölch, W., von Kriegsheim, A., Dorotikova, A., et al. (2024) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2321305121 · Cited by 12
Tau uptake by human neurons depends on receptor LRP1 and kinase LRRK2
Evans, L. D., Strano, A., Tuck, E., Campbell, A., Smith, J., Hung, C., Behr, T. S., Ghetti, B., Ryskeldi-Falcon, B., Karakoc, E., et al. (2025) · The EMBO Journal · doi:10.1038/s44318-025-00514-0 · Cited by 16
Self-citationDiversification of the CRISPR Toolbox: Applications of CRISPR-Cas Systems Beyond Genome Editing
Balderston, S., Clouse, G., Ripoll, J. J., Pratt, G. K., Gasiūnas, G., Bock, J.-O., Bennett, E., & Aran, K. (2021) · The CRISPR Journal · doi:10.1089/crispr.2020.0137 · Cited by 14
Common computational tools for analyzing CRISPR screens
Colic, M., & Hart, T. (2021) · Emerging Topics in Life Sciences · doi:10.1042/etls20210222 · Cited by 13
Jiang, J., Sun, Y., Wang, Y., Sabek, A., Shangguan, A., Wang, K., Zhao, S., Li, G., Zhou, A., & Zhang, S. (2022) · Virus Research · doi:10.1016/j.virusres.2022.198738 · Cited by 13
Gonzalez-Salinas, F., Martínez-Amador, C., & Treviño, V. (2022) · Gene · doi:10.1016/j.gene.2022.146595 · Cited by 12
UTP18-mediated p21 mRNA instability drives adenoma-carcinoma progression in colorectal cancer
Pan, M., Xiao, T., Xu, L., Xie, Y., & Ge, W. (2023) · Cell Reports · doi:10.1016/j.celrep.2023.112423 · Cited by 14
Occhipinti, A., Hamadi, Y., Kugler, H., Wintersteiger, C. M., Yordanov, B., & Angione, C. (2020) · IEEE Transactions on Computational Biology and Bioinformatics · doi:10.1109/tcbb.2020.2973386 · Cited by 13
Establishment and characterization of novel patient-derived cell lines from giant cell tumor of bone
Yoshimatsu, Y., Noguchi, R., Tsuchiya, R., Ono, T., Sin, Y., Sei, A., Sugaya, J., Mori, T., Fukushima, S., Yoshida, A., et al. (2021) · Human Cell · doi:10.1007/s13577-021-00579-z · Cited by 13
Kikuchi, S., Green, J. C., Rogness, D. C., Lam, B., Owyang, Z. A., Malmstrom, R. D., Tabatabaei, A., Snead, A. N., Hoffman, M. A., Bernard, S. M., et al. (2025) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5c01805 · Cited by 15
Dissecting Molecular Phenotypes Through FACS-Based Pooled CRISPR Screens
Genolet, O., Lustig, L. R., & Schulz, E. G. (2022) · Methods in molecular biology · doi:10.1007/7651_2021_457 · Cited by 12
Emerging target discovery and drug repurposing opportunities in chordoma
Freed, D. M., Sommer, J., & Punturi, N. B. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.1009193 · Cited by 11
Park, M., Kim, D., Kim, I., Im, S., & Kim, S. (2023) · EBioMedicine · doi:10.1016/j.ebiom.2023.104705 · Cited by 12
Zhang, Z., & Zhu, Q. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241512494 · Cited by 13
Du, Y., Luo, L., Xu, X., Yang, X., Yang, X., Xiong, S., Yu, J., Liang, T., & Guo, L. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15102433 · Cited by 14
CDS-DB, an omnibus for patient-derived gene expression signatures induced by cancer treatment
Liu, Z., Chen, R., Yang, L., Jiang, J., Ma, S., Chen, L., He, M., Mao, Y., Guo, C., Kong, X., et al. (2023) · Nucleic Acids Research · doi:10.1093/nar/gkad888 · Cited by 12
ZMIZ1 enhances ERα-dependent expression of E2F2 in breast cancer
Zhao, W., Rose, S. F., Blake, R., Godicelj, A., Cullen, A. E., Stenning, J., Beevors, L., Gehrung, M., Kumar, S., Kishore, K., et al. (2024) · Journal of Molecular Endocrinology · doi:10.1530/jme-23-0133 · Cited by 14
CRISPR-Cas9 screens reveal common essential miRNAs in human cancer cell lines
Merk, D. J., Paul, L., Tsiami, F., Hohenthanner, H., Mohseni-Kouchesfahani, G., Haeusser, L. A., Walter, B., Brown, A., Persky, N. S., Root, D. E., et al. (2024) · Genome Medicine · doi:10.1186/s13073-024-01341-4 · Cited by 12
Salvati, A., Giurato, G., Lamberti, J., Terenzi, I., Crescenzo, L., Melone, V., Palo, L., Giordano, A., Sabbatino, F., Roscigno, G., et al. (2024) · Molecular Cancer · doi:10.1186/s12943-024-02071-2 · Cited by 12
NF-κB-activated oncogene inhibition strategy for cancer gene therapy
Dai, W., Wu, J. Y., Shui, Y., Wu, Q., Wang, J., & Xia, X. (2024) · Cancer Gene Therapy · doi:10.1038/s41417-024-00828-x · Cited by 11
Abecunas, C., Kidd, A. D., Jiang, Y., Zong, H., & Fallahi‐Sichani, M. (2024) · Cell Reports · doi:10.1016/j.celrep.2024.114775 · Cited by 14
Iacovacci, J., Brough, R., Moughari, F. A., Alexander, J. J., Kemp, H., Tutt, A. N. J., Natrajan, R., Lord, C. J., & Haider, S. A. (2025) · Science Advances · doi:10.1126/sciadv.adq9495 · Cited by 13
Kim, D. V., Kulishova, L. M., Torgasheva, N. A., Melentyev, V. S., Dianov, G. L., Medvedev, S. P., Zakian, S. M., & Zharkov, D. O. (2021) · PLoS ONE · doi:10.1371/journal.pone.0257473 · Cited by 11
Kang, H. G., Hwangbo, H., Kim, M. J., Kim, S., Lee, E. J., Park, M. J., Kim, J.-W., Kim, B.-G., Cho, E.-H., Chang, S., et al. (2021) · Cancer Research · doi:10.1158/0008-5472.can-21-2023 · Cited by 14
McLean, B. J., Istadi, A., Clack, T., Vankan, M., Schramek, D., Neely, G. G., & Pajic, M. (2022) · Advanced Genetics · doi:10.1002/ggn2.202200014 · Cited by 12
Insights into the aberrant CDK4/6 signaling pathway as a therapeutic target in tumorigenesis
Rezaeian, A.-H., Inuzuka, H., & Wei, W. (2022) · Advances in protein chemistry and structural biology · doi:10.1016/bs.apcsb.2022.11.009 · Cited by 12
Metaboverse enables automated discovery and visualization of diverse metabolic regulatory patterns
Berg, J. A., Zhou, Y., Ouyang, Y., Cluntun, A. A., Waller, T. C., Conway, M. E., Nowinski, S. M., Ry, T. V., George, I. D., Cox, J. E., et al. (2023) · Nature Cell Biology · doi:10.1038/s41556-023-01117-9 · Cited by 19
Poser, S., Otto, O., Arps‐Forker, C., Ge, Y., Herbig, M., Andree, C., Gruetzmann, K., Adasme, M. F., Stodolak, S., Nikolakopoulou, P., et al. (2019) · The FASEB Journal · doi:10.1096/fj.201802603rr · Cited by 12
Ayestaran, I., Galhoz, A., Spiegel, E., Sidders, B. S., Dry, J. R., Dondelinger, F., Bender, A., McDermott, U., Iorio, F., & Menden, M. P. (2020) · Patterns · doi:10.1016/j.patter.2020.100065 · Cited by 12
Self-citation
Metadata
- Authors
- Behan, F. M., Iorio, F., Picco, G., Gonçalves, E., Beaver, C. M., Migliardi, G., Santos, R., Rao, Y., Sassi, F., Pinnelli, M., Ansari, R., Harper, S., Jackson, D. A., McRae, R., Pooley, R., Wilkinson, P., van der Meer, D., Dow, D., Buser-Doepner, C., Bertotti, A., Trusolino, L., Stronach, E. A., Saez-Rodriguez, J., Yusa, K., & Garnett, M. J.
- Affiliations
- Wellcome Sanger Institute (GB)
- European Bioinformatics Institute (GB)
- Candiolo Cancer Institute (IT)
- GlaxoSmithKline (United Kingdom) (GB)
- GlaxoSmithKline (United States) (US)
- Kyoto University (JP)
- Corresponding author
- Yusa, Kosuke
- Garnett, Mathew J.
- ORCID
- Venue
- Nature
- Published
- 2019-04-10
- Volume
- 568
- Issue
- 7753
- Pages
- 511-516
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W2936686072
- Cited by
- 1,338
- References
- 64
- Citations by year
- 2026: 129 · 2025: 168 · 2024: 200 · 2023: 158 · 2022: 200 · 2021: 227 · 2020: 179 · 2019: 74
- FWCI
- 56.69
- Type
- journal article
- Language
- en
- Open access
- green
- doi.org
- Licence
- Locations
- Nature (publishedVersion)
- bioRxiv (Cold Spring Harbor Laboratory) (acceptedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Institutional Research Information System University of Turin (University of Turin) (submittedVersion, other-oa)
- RePEc: Research Papers in Economics (submittedVersion)
- RWTH Publications (RWTH Aachen) (submittedVersion)
- Funders
- Wellcome Trust (C44943/A22536, SU2C-AACR-DT1213, 102696, 206194)
- Cancer Research UK (A22536, SU2C-AACR-DT1213, 102696, C44943/A22536)
- Associazione Italiana per la Ricerca sul Cancro (5X 1000, 21091, 20697, 18532)
- Stand Up To Cancer (SU2C-AACRDT1213)
- H2020 European Research Council (724748)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › CRISPR and Genetic Engineering
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Chromatin Remodeling and Cancer
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
- Keywords
- cancer cell lines, synthetic lethality, microsatellite instability, cancer dependency, genomic biomarkers, anticancer drug development
- MeSH terms
- Werner Syndrome Helicase, Synthetic Lethal Mutations, Gene Editing, Animals, Female, Humans, Neoplasm Transplantation, Neoplasms, Organ Specificity, Biomarkers, Tumor, Werner Syndrome, Reproducibility of Results, Genome, Human, Cell Line, Tumor, Mice, Microsatellite Instability, Drug Discovery, Molecular Targeted Therapy, CRISPR-Cas Systems
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
